• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Fulvestrant Rompharm
    / A.L. Medi-Market LTD,


    Active Ingredient
    Fulvestrant 250 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Pre-filled syringe (Solution for injection or infusion)

    2 X 5 ml

    partial basket chart

    Related information


    Dosage

    Please refer to the license holder for further details


    Indications

    Treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with hormonal therapy, or with disease relapse/progression on or after adjuvant endocrine therapy.

    In combination with the preparation Palbociclib or Abemaciclib, is intended for women with advanced or metastatic estrogen receptor-positive and HER2-negative breast cancer, whose disease has progressed after receiving prior hormonal treatment for this ailment.

    In combination with Ribociclib, is intended for men and postmenopausal women with advanced or metastatic estrogen receptor-positive and HER2-negative breast cancer, whose disease has progressed after receiving prior endocrine treatment for this ailment or as initial endocrine treatment.


    Contra-Indications

    Please refer to the license holder for further details


    Special Precautions

    Please refer to the license holder for further details


    Side Effects

    Please refer to the license holder for further details


    Drug interactions

    Please refer to the license holder for further details


    Pregnancy and Lactation

    Please refer to the license holder for further details


    Overdose

    Please refer to the license holder for further details


    Manufacturer
    Rompharm Company S.R.L
    CLOSE